Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. The impact of tobacco smoking on survival of patients with oral squamous cell carcinoma: a population-based retrospective study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Baseline FDG PET/CT in free breathing versus deep inspiration breath-hold for pediatric patients with mediastinal lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Real-world data on melanoma brain metastases and survival outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Synthetic 4DCT(MRI) lung phantom generation for 4D radiotherapy and image guidance investigations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mette T Mouritzen
  • Karen F Junker
  • Andreas Carus
  • Morten Ladekarl
  • Peter Meldgaard
  • Anders W M Nielsen
  • Anna Livbjerg
  • Jacob W Larsen
  • Halla Skuladottir
  • Charlotte Kristiansen
  • Kim Wedervang
  • Tine Schytte
  • Karin H Hansen
  • Anne-Cathrine Østby
  • Malene S Frank
  • Jakob Lauritsen
  • Jens B Sørensen
  • Seppo W Langer
  • Gitte F Persson
  • Jon L Andersen
  • Pernille H Homann
  • Emilie B Kristensen
  • Lars B Drivsholm
  • Martin Bøgsted
  • Heidi S Christensen
  • Mette Pøhl
  • Birgitte Bjørnhart
Vis graf over relationer

BACKGROUND: Immune checkpoint inhibitors (ICIs) are implemented as standard treatment for patients with advanced non-small cell lung cancer (NSCLC) in first-line and subsequent-line treatment. However, certain subgroups such as patients with older age, poor performance status (PS), and severe comorbidity are underrepresented in the randomized controlled trials (RCTs). This study aimed to assess overall survival (OS), treatment data, and clinical features affecting second- or subsequent-line ICI efficacy in an unselected, Danish, nationwide NSCLC population.

METHODS: Patients with advanced NSCLC who started nivolumab or pembrolizumab as second-line or subsequent-line treatment between 1 September 2015, and 1 October 2018, were identified from institutional records of all Danish oncology departments. Clinical and treatment data were retrospectively collected. Descriptive statistics and survival analyses were performed.

RESULTS: Data were available for 840 patients; 49% females. The median age was 68 years (19% were ≥75 years), 19% had PS ≥2, and 36% had moderate to severe comorbidity. The median OS (mOS) was 12.2 months; 15.1 months and 10.0 months in females and males, respectively. The median time-to-treatment discontinuation (mTTD) and median progression-free survival (mPFS) was 3.2 and 5.2 months, respectively. Patients with PS ≥2 had a mOS of 4.5 months, mTTD of 1.1 month, and mPFS of 2.0 months. In multivariable Cox regression analysis, male sex (HR = 1.35, 95% CI 1.11-1.62), PS >0 (PS 1, HR = 1.88, 95% CI 1.52-2.33; PS ≥2, HR = 4.15, 95% CI 3.13-5.5), liver metastases (HR = 1.72, 95% CI 1.34-2.22), and bone metastases (HR = 1.27, 95% CI 1.03-1.58) were significant poor prognostic OS factors.

CONCLUSIONS: Danish real-world patients with advanced NSCLC treated with second- or subsequent-line ICI had an OS comparable to results from RCTs. Women, frail and older patients constituted a higher proportion than in previous RCTs. Clinical features associated with poor OS were male sex, PS ≥1 (in particular PS ≥2), bone-, and liver metastases.

OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind61
Udgave nummer4
Sider (fra-til)409-416
Antal sider8
ISSN0284-186X
DOI
StatusUdgivet - apr. 2022

ID: 70608223